A prognostic biomarker for immunotherapy of biliary tract cancer

Through the expression analysis of ARID1A protein and the combination of anti-mouse PD-1 antibodies and other drugs, a prognosis and efficacy model of biliary cancer immunotherapy was constructed, which solved the problem of poor efficacy of biliary cancer immunotherapy, and achieved accurate screening of patients and Improved treatment effect.

CN118655319BActive Publication Date: 2024-12-03ZHEJIANG CANCER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411148836.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-12-03
Estimated Expiration
2044-08-21

AI Technical Summary

Technical Problem

The prognosis of biliary cancer is poor, and the current immunotherapy effect is limited. Especially in advanced biliary cancer, patients have low response rate to chemotherapy combined with immunotherapy, and the frequency of targeted gene mutations is low, making it difficult to accurately screen out the effectiveness of immunotherapy. crowd.

Method used

Using ARID1A protein as a biomarker, the prognostic evaluation model for biliary cancer immunotherapy is constructed through its expression level, and combining anti-mouse PD-1 antibodies and other drugs such as gemcitabine to construct a therapeutic efficacy prediction model to improve the targeted and effective treatment .

Benefits of technology

The expression analysis of ARID1A protein can more accurately screen out the patient population that may benefit from immunotherapy, provide accurate immunotherapy strategies, improve the targeted and effective treatment of biliary cancer, and reduce adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118655319B_ABST
    Figure CN118655319B_ABST
Patent Text Reader

Abstract

The present invention discloses a biomarker for the prognosis of biliary tract cancer immunotherapy, which belongs to the field of biomedicine technology, and specifically provides ARID1A chemokine as a predictive biomarker for the efficacy of biliary tract cancer immunotherapy. The discovery of this biomarker can improve the current efficacy prediction model of biliary tract cancer immunotherapy, thereby more accurately screening out the patient population that may benefit from immunotherapy. On the other hand, the present invention aims to provide accurate immunotherapy strategies for biliary tract cancer patients through the role of ARID1A molecules in biliary tract cancer immunotherapy, guide clinicians to formulate personalized treatment plans for patients, improve the pertinence and effectiveness of treatment, and reduce adverse reactions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a biomarker for the prognosis of biliary tract cancer immunotherapy. Background Art

[0002] Biliary tract cancer (BTC) includes cholangiocarcinoma (cancer occurring in the liver, around the liver hilum, or at the distal end of the bile duct) and gallbladder cancer. For decades, the overall prognosis of biliary tract cancer has been almost stagnant. Due to the occult and atypical early clinical symptoms of biliary tract cancer, nearly two-thirds of biliary tract cancer patients are already in an unresectable or distant metastatic state when they are diagnosed, so systemic therapy is the main treatment option. However, the efficacy of chemotherapy alone is not significant. In the first-line treatment, the gemcitabine combined with cisplatin (GemCis) regimen can only extend the median overall survival (mOS) to 11.7 months, and it is urgent to find other treatment options.

[0003] In recent years, personalized precision treatment based on immunity and targeting has become a new treatment strategy that has changed clinical practice. Due to the low mutation frequency of targetable genes such as IDH1, FGFR and BRAF in biliary tract cancer (<5%), the population that benefits from second-line targeted therapy is still very limited. Immunotherapy has made breakthroughs in many solid tumors in recent years, but has made slow progress in the field of biliary tract cancer. It was not until the TOPAZ-1 (NCT03875235) study that a breakthrough in chemotherapy combined with immunotherapy was achieved in the first-line treatment of advanced biliary tract cancer. GemCis combined with durvalumab can extend mOS to 12.8 months, but the objective response rate (ORR) is only 26.7%, indicating that only a small number of people benefit from immunotherapy. Therefore, accurate screening of immune-dominant populations to protect non-responders from adverse reactions has important social benefits and is a research hotspot and difficulty in the current field of biliary tract cancer immunotherapy.

[0004] ARID1A belongs to the SWI / SNF complex, which is an ATP-dependent chromatin remodeling complex composed of multiple subunits and has multiple functions: mobilizing promoters and enhancers; promoting the binding of transcription factors; recruiting histone modification enzymes, etc., regulating gene expression by changing chromosome structure and accessibility, and mutating or inactivating in about 20% of human cancers. Previous studies on ARID1A have mainly focused on signaling pathways within tumor cells. For example, the glutathione inhibitor APR-246 is used to treat ARID1A-mutated ovarian clear cell carcinoma through synthetic lethality; ARID1A and KRAS co-mutations promote biliary cancer tumor growth by inhibiting the TGF-β-Smad signaling axis. In recent years, the role of ARID1A in the immune microenvironment has also been gradually reported. For example, the proportion of M1-like macrophages in tumor tissues of patients with ARID1A-mutated biliary cancer increases, resulting in a pro-inflammatory phenotype immune microenvironment in biliary cancer tissues. For example, ARID1A can inhibit the occurrence of ovarian cancer, and ARID1A deficiency downregulates the mevalonate pathway and inhibits the effect of T cell-based immunotherapy. Summary of the invention

[0005] Biomarkers are indicators that can be objectively measured and evaluated, reflecting physiological or pathological processes, and producing biological effects on exposure or therapeutic interventions. Currently, a variety of biomarkers, including programmed cell death ligand 1 (PD-L1) protein expression, tumor mutation burden (TMB), mismatch repair deficiency (dMMR) and microsatellite instability (MSI), have been shown to be associated with the benefits of immunotherapy for solid tumors, but research in biliary malignancies is still in the exploratory stage. PD-L1 expression is a widely studied biomarker in biliary cancer, but it was not significantly associated with ICI treatment sensitivity in the TOPAZ-1 study.

[0006] The purpose of the present invention is to provide a biliary tract cancer biomarker ARID1A, which can be used to construct a prognostic evaluation model for biliary tract cancer patients receiving first-line chemotherapy combined with immunotherapy; and the chemokine ARID1A can regulate the immune microenvironment of biliary tract cancer and is a potential immunotherapy target.

[0007] The technical solution adopted by the present invention to achieve the above-mentioned purpose is:

[0008] A prognostic biomarker for immunotherapy of biliary tract cancer, comprising: ARID1A protein.

[0009] Preferably, the expression level of ARID1A protein is overexpressed.

[0010] The invention discloses use of a biliary tract cancer immunotherapy prognosis biomarker in preparing a biliary tract cancer immunotherapy drug. The biliary tract cancer immunotherapy prognosis biomarker is ARID1A protein.

[0011] Preferably, the expression level of ARID1A protein is overexpressed.

[0012] The present invention discloses a method for constructing an efficacy prediction model for immunotherapy of biliary tract cancer based on ARID1A, comprising:

[0013] Cholangiocarcinoma cells are taken out from cholangiocarcinoma patients, and the expression of ARID1A in the cholangiocarcinoma cells is analyzed and compared with the expression of ARID1A in normal cholangiocytes. Any of the results (1)-(2) is obtained:

[0014] Results (1): ARID1A expression in cholangiocarcinoma cells was high, indicating a good prognosis;

[0015] Result (2): ARID1A expression in cholangiocarcinoma cells was low, suggesting a poor prognosis.

[0016] Preferably, the product for use in treating results (1)-(2) comprises at least an anti-mouse PD-1 antibody and gemcitabine.

[0017] More preferably, the use product further comprises a hydroxylamine ester-based compound having a methionine group and an acetohydroxamic acid group.

[0018] More preferably, the amount of the anti-mouse PD-1 antibody used is 1-10 mg / kg, and the amount of gemcitabine used is 5-50 mg / kg.

[0019] More preferably, the amount of the hydroxylamine ester compound used is 1-10 mg / kg.

[0020] The present invention discloses the use of anti-mouse PD-1 antibody and gemcitabine in preparing a medicine for treating biliary tract cancer having the above-mentioned biliary tract cancer immunotherapy prognostic biomarker.

[0021] Preferably, the ratio of anti-mouse PD-1 antibody to gemcitabine is 1:0.5-50.

[0022] The present invention discloses a method for constructing an ARID1A-based efficacy prediction model for biliary tract cancer treatment, comprising:

[0023] Screening patients to select qualified cholangiocarcinoma patients; taking out cholangiocarcinoma cells from qualified cholangiocarcinoma patients, analyzing the expression of ARID1A in the cholangiocarcinoma cells, and obtaining any one of the results (1)-(2):

[0024] Results (1): ARID1A expression was high in cholangiocarcinoma cells, indicating a good therapeutic effect;

[0025] Result (2): ARID1A expression in cholangiocarcinoma cells was low, indicating poor therapeutic effect.

[0026] Preferably, the product used in the treatment of results (1)-(2) includes at least an anti-PD-1 antibody and gemcitabine.

[0027] Preferably, the use product further comprises a hydroxylamine ester compound having a methionine group and an acetohydroxamic acid group.

[0028] Preferably, the anti-mouse PD-1 antibody is used in an amount of 1-10 mg / kg, and the gemcitabine is used in an amount of 5-50 mg / kg.

[0029] Preferably, the hydroxylamine ester compound is used in an amount of 1-10 mg / kg.

[0030] The present invention discloses the use of anti-PD-1 antibody and gemcitabine in preparing a medicine for treating biliary tract cancer having the above-mentioned biliary tract cancer immunotherapy prognostic biomarker.

[0031] Preferably, the ratio of anti-PD-1 antibody to gemcitabine is 1:0.5-50.

[0032] The present invention discloses the use of an anti-PD-1 antibody, a hydroxylamine ester compound and gemcitabine in preparing a drug for treating biliary tract cancer having the above-mentioned biliary tract cancer immunotherapy prognostic biomarker.

[0033] Preferably, the anti-PD-1 antibody, the hydroxylamine ester compound and gemcitabine are used in a ratio of 1:0.1-10:0.5-50.

[0034] Preferably, in the preparation of the hydroxylamine ester compound, methionine is added to dichloromethane, stirred at 0-10°C for 10-30 minutes, then N,N-carbonyldiimidazole is added, stirred and mixed for 10-60 minutes, and then the temperature is raised to 2-40°C, and then acetohydroxamic acid is added to react for 2-6 hours. After the reaction is completed, it is concentrated under reduced pressure and separated by column chromatography to obtain the hydroxylamine ester compound.

[0035] More preferably, in the preparation of the hydroxylamine ester compound, the amount of methionine used is 3-9 wt % of dichloromethane.

[0036] More preferably, in the preparation of the hydroxylamine ester compound, the amount of N,N-carbonyldiimidazole used is 80-120 wt % of methionine.

[0037] More preferably, in the preparation of the hydroxylamine ester compound, the amount of acetohydroxamic acid used is 80-120 wt % of methionine.

[0038] More preferably, in the preparation of the hydroxylamine ester compound, in the column chromatography separation, the eluent is a mixture of methanol and water, and the methanol and water in the eluent are mixed in a volume ratio of 1:0.5-3.

[0039] The present invention discloses the use of an anti-PD-1 antibody, a hydroxylamine ester compound, glycyl D-glutamine and gemcitabine in preparing a drug for treating biliary tract cancer having the above-mentioned biliary tract cancer immunotherapy prognostic biomarker.

[0040] Preferably, the anti-PD-1 antibody, the hydroxylamine ester compound, glycyl D-glutamine and gemcitabine are used in a ratio of 1:0.1-10:0.05-2:0.5-50.

[0041] The purpose of the present invention is to provide a biliary tract cancer biomarker ARID1A, which can be used to construct a prognostic evaluation model for biliary tract cancer patients receiving first-line chemotherapy combined with immunotherapy; and the chemokine ARID1A can regulate the immune microenvironment of biliary tract cancer and is a potential immunotherapy target.

[0042] The beneficial effects of the technical solution of this case are: (1) New biomarker: The present invention provides ARID1A chemokine as a predictive biomarker for the efficacy of immunotherapy for biliary tract cancer. The discovery of this biomarker can improve the current efficacy prediction model for immunotherapy for biliary tract cancer, thereby more accurately screening out the patient population that may benefit from immunotherapy. (2) Precision immunotherapy: The present invention aims to provide a precise immunotherapy strategy for biliary tract cancer patients through the role of ARID1A molecules in immunotherapy for biliary tract cancer, guide clinicians to develop personalized treatment plans for patients, improve the pertinence and effectiveness of treatment, and reduce adverse reactions. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 This is a graph showing ARID1A expression and patient prognosis;

[0044] Figure 2 This is the result diagram of low CXCL9 gene expression;

[0045] Figure 3 It is the gene expression graph of CTLA4, PDCD1, CD274 and PDCD1LG2;

[0046] Figure 4This is the result diagram of the expression of transforming growth factor-β signaling pathway;

[0047] Figure 5 This is a graph showing the efficacy of ARID1A high expression enhancing immunotherapy combined with chemotherapy.

[0048] Figure 6 Cell inhibition rate graph. DETAILED DESCRIPTION

[0049] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0050] The following first describes the concepts involved in the present application in conjunction with the accompanying drawings. It should be noted that the following description of each concept is only to make the content of the present application easier to understand, and does not limit the scope of protection of the present application; at the same time, the embodiments and features in the embodiments of the present application can be combined with each other in the absence of conflict. The present application will be described in detail with reference to the accompanying drawings and in conjunction with the embodiments.

[0051] Embodiments of the present invention:

[0052] 1. Patient Enrollment and Data Collection

[0053] The study period of the method of the present invention is from November 2017 to August 2022. Patients are screened by inclusion and exclusion criteria, and eligible patients are registered and data are collected.

[0054] Screening criteria for patient enrollment were: patients aged 18 years or older, with histologically confirmed unresectable advanced or metastatic biliary adenocarcinoma (including intrahepatic or extrahepatic cholangiocarcinoma and gallbladder cancer) who had received first-line immune checkpoint inhibitors (ICIs) in combination with chemotherapy. Detailed inclusion and exclusion criteria are shown in the table below.

[0055]

[0056] Collection of patient data: All medical records of eligible patients were reviewed, and the genomic and transcriptomic landscapes of baseline tissues were analyzed. PFS was measured from the start of treatment to disease progression or death (whichever came first). OS was defined as the time from the start of treatment to death. Eligible patients who were receiving treatment or had no confirmed progression were reviewed at the time of the last follow-up. The above study was approved by the Ethics Committee of Zhejiang Cancer Hospital (approval number: IRB-2020-404) and complied with the Declaration of Helsinki. Informed consent was obtained from all participating patients.

[0057] 2. DNA Extraction, Library Preparation, and Targeted DNA Sequencing

[0058] Genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples using the QIAamp DNA FFPE Tissue Kit provided by Qiagen. Subsequently, the DNA quantity and quality were assessed using the Qubit 3.0 Fluorometer (Thermo Fisher Scientific) and Nanodrop 2000 (Thermo Fisher Scientific), respectively. The creation of sequencing libraries was completed using the KAPA Hyper Prep Kit from KAPA Biosystems. Hybridization-based target enrichment was performed using the Geneseeq Prime® Pan-Cancer Genome and the xGen Lockdown Hybridization and Washing Kit (Integrated DNA Technology). Library capture was performed using Life Technologies' Dynabeads M-270, followed by amplification using KAPA HiFi HotStart ReadyMix from KAPA Biosystems. Library quantification was performed using qPCR and the KAPA Library Quantification Kit from KAPA Biosystems. Finally, the library was sequenced on the Illumina Hiseq4000 platform.

[0059] 3. Bioinformatics Analysis of DNA Sequencing Data

[0060] Trimmomatic was used to perform quality control on FASTQ files, trim leading or trailing low-quality bases (bases with a quality score lower than 20) and remove N bases. Subsequently, the sequencing data were aligned to the reference human genome (hg19) using Burrows-Wheeler Aligner (BWA-mem, v0.7.12), and the alignment results were deduplicated using Sambaba. Base quality realignment and indel realignment were performed using the Genome Analysis Toolkit (GATK 3.4.0). Variant calling, including single nucleotide variants (SNVs) and insertions / deletions (INDELs), was performed using VarScan2. Genomic fusions were identified using FACTERA with default parameters, and copy number variations (CNVs) were detected using CNVkit with default parameters, applying a threshold of 0.6 for copy number loss and 2.0 for copy number gain. Tumor mutation burden (TMB) was defined as the number of somatic mutations, coding mutations, base substitution mutations, and indel mutations per megabase of the genome examined. Microsatellite instability (MSI) was defined as samples showing instability in more than 40% of the 52 indel sites covered by the panel.

[0061] 4. RNA Sequencing and Bioinformatics Analysis

[0062] Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples using the RNeasy FFPE kit (QIAGEN), and RNA quantity was assessed using the Bioanalyzer 2100 (Agilent Technologies). To eliminate ribosomal RNA and any remaining genomic DNA, enzymatic digestion was performed using RNase H and DNase. Subsequently, sequencing libraries were constructed using the KAPA Stranded RNA-Seq Library Preparation Kit with RiboErase (HMR) (KAPA Biosystems). Library quality was verified using the Agilent High Sensitivity DNA Kit on the Bioanalyzer 2100 (Agilent Technologies) and then sequenced on the Illumina HiSeq NGS platform (Illumina).

[0063] Illumina bcl2Fastq software (v2.19.0.316) was used for base calling to generate sequence reads in FASTQ format. Trimmomatic (v0.36) was used to remove adapters and low-quality reads. Transcriptome mapping was performed by STAR software (v2.7.3a) and the data were aligned to the reference human genome (hg19). Gene-level quantification was performed using RSEM (version 1.2.31), and gene expression was quantified as transcripts per million (TPM). Gene set enrichment analysis (GSEA) was performed using fgsea (v1.20.0), and statistical significance was defined as |NES| ≥ 1.5 and P-adjusted < 0.1.

[0064] 5. Immune Infiltration Analysis

[0065] The proportion of tumor-infiltrating immune cells was estimated using xCell. The TME score was estimated using the R package TMEscore (https: / / github.com / DongqiangZeng0808 / TMEscore). T cell dysfunction and exclusion scores were assessed using Tumor Immune Dysfunction and Exclusion (TIDE, http: / / tide.dfci.harvard.edu).

[0066] 6. Statistical Analysis

[0067] In genomic and transcriptomic comparisons, Fisher’s exact test was used to assess differences in categorical variables between the groups, whereas Wilcoxon rank-sum test was used to determine differences in continuous variables between these groups. In animal and cell line experiments, Student’s unpaired t-test and one-way ANOVA (Tukey’s and Bonferroni’s multiple comparison tests) were used, and Wilcoxon rank-sum test was used to assess differences between IHC staining of patient resection specimens. The Cochran–Armitage test was used to assess trends (either increasing or decreasing) in proportions of specific binary categorical variables, whereas Jonckheere’s trend test was used to assess trends regarding ordinal variables. Spearman’s Rho correlation coefficient was used to analyze associations between continuous features. Survival analysis involved the generation of PFS and OS curves with their respective 95% confidence intervals (CIs) using the Kaplan–Meier method and comparisons using the log-rank test. Hazard ratios (HRs) were calculated and compared using univariate Cox proportional hazards regression models. To account for multiple comparisons, false discovery rate (FDR) correction was implemented.

[0068] Unless otherwise stated, two-tailed P values ​​< 0.05 were considered statistically significant. All statistical analyses were performed using R software (v4.1.2).

[0069] 7. Immunohistochemical Staining

[0070] Mouse cholangiocarcinoma tissues were collected after formalin fixation, paraffin embedding, and sectioning. The sections were dewaxed, rinsed with distilled water, and then antigen retrieval was performed, and washed with PBS for 5 minutes × 3 times. Then, the primary antibody ARID1A (CST, 12354, 1:800) was added, incubated at 4°C overnight, and washed with PBS for 5 minutes × 3 times; then goat anti-rabbit IgG H&L (Biotin) (dilution ratio 1:1000) was added to the tissue sections, incubated for 30 minutes, and washed with PBS for 5 minutes × 3 times; then DAB color development and hematoxylin counterstaining of cell nuclei were performed using a DAB color development kit; finally, the tissue sections were dehydrated and blocked with neutral gel. Tumor sections were screened at low magnification (100×), and immunoreactivity was evaluated at high magnification (400×). All immunohistochemical staining sections were examined and evaluated by two independent pathologists in a blinded manner. The fold change of ARID1A expression intensity in the overexpression group relative to that in the control group was >2, and P<0.05 was used as the successful standard for ARID1A overexpression. In addition, the daily scoring system was used to evaluate the expression intensity of ARID1A in the tumor tissues of the two groups of mice. The formula of the H-scoring system is as follows: Hscore=(∑IS×AP), where IS represents the staining intensity and AP represents the percentage of positively stained cells. IS depends on the staining of the cells: no staining is 0 points; weak staining is 1 point; moderate staining is 2 points; strong staining is 3 points, and the percentage of AP-stained cells: 0% is 0 points; 1%-25% is 1 point; 26%-50% is 2 points; 51%-75% is 3 points; 6%-100% is 4 points. The median of H-score was set as the cutoff value, and the expression of ARIDIA in mouse tumor tissues was divided into a high expression group (H-score>4) and a low expression group (H-score≤4).

[0071] In the method of the present invention, the expression of ARIDIA in any cell can be judged and applied by using the H scoring system for high expression and low expression.

[0072] The results of the above research implementation methods of the present invention are as follows:

[0073] 1. Patient characteristics

[0074] The above study enrolled 125 patients with advanced BTC who received first-line immune checkpoint inhibitors combined with chemotherapy between November 2017 and August 2022, including 54 patients with gallbladder cancer (GC), 57 patients with intrahepatic cholangiocarcinoma (ICC), and 14 patients with extrahepatic cholangiocarcinoma (ECCA). The median age of patients with advanced BTC was 63 years (range, 34 to 82 years), of which 52.8% (66 / 125) were male. The median follow-up time of patients with advanced BTC was 14.8 months, and the median PFS and OS were 6.9 months (95% CI: 6.2-7.9 months) and 11.8 months (95% CI: 10.3-14.8 months), respectively. The median PFS of GC, ICC, and ECCA patients were 6.83, 6.93, and 6.77 months, and the median OS were 11.10, 12.75, and 8.61 months, respectively, and no significant differences were observed (PFS: P = 0.720, OS: P = 0.714).

[0075] All 125 patients underwent targeted DNA sequencing, and an additional 62 patients underwent RNA sequencing. The most mutated genes were TP53 (64 / 125, 51.2%), KRAS (34 / 125, 27.2%), ERBB2 (18 / 125, 14.4%), and ARID1A (17 / 125, 13.6%).

[0076] 2. Relationship between ARID1A expression and patient prognosis

[0077] The statistical results are as follows Figure 1 As shown, A is the progression-free survival (PFS) and B is the overall survival (OS). In patients receiving combined chemotherapy and immunotherapy, the PFS and OS of ARID1A gene mutation patients were shorter than those of wild-type patients (mPFS: 5.39 months vs 7.10 months, P=0.008; mOS: 7.97 months vs 12.19 months, P=0.012).

[0078] 3. Immune microenvironment of patients with ARID1A gene mutation

[0079] Patients with ARID1A gene mutation had lower expression of chemokine CXCL9 gene. Figure 2 shown.

[0080] The expression levels of CTLA4 (P=0.097) and PDCD1 (P=0.059) genes in patients with ARID1A gene mutation were slightly lower than those in wild-type patients, while the expression levels of CD274 and PDCD1LG2 genes were not statistically different between the two groups. Figure 3 shown.

[0081] The expression of transforming growth factor-β signaling pathway in patients with ARID1A gene mutation was upregulated compared with the wild type, and the standardized enrichment score and corresponding P value were as follows Figure 4 shown.

[0082] 4. In vivo experiments verify that high expression of ARID1A enhances the efficacy of combined immunotherapy and chemotherapy

[0083] We established a mouse cholangiocarcinoma model by hydrodynamic transfection of AKT / YAP(S127A) plasmids. YAP(S127A) was pT3-EF1a-YapS127A, and AKT was pT3-myr-AKT-HA. At the same time, we co-injected the constructed ARID1A overexpression plasmid into mice by hydrodynamic co-injection to achieve overexpression of ARID1A in cholangiocarcinoma tissues. Anti-mouse PD-1 antibody and gemcitabine were intraperitoneally administered to mice on days 10 and 17. Mice were killed on day 24 and livers were collected. There were 7 mice in each group. A control group was set up. The control group also established a mouse cholangiocarcinoma model by hydrodynamic transfection of AKT / YAP(S127A) plasmids without constructing ARID1A overexpression. The results are shown in Figure 5 As shown in Figure 2, compared with the control group, immunotherapy combined with chemotherapy delayed the progression of cholangiocarcinoma in mice. Notably, overexpression of ARID1A further enhanced the efficacy of chemotherapy combined with immunotherapy and significantly reduced the tumor burden in mice. Figure 5 As shown in A, the liver weights of each group were Figure 5 As shown in B. ARID1A immunohistochemical staining analysis confirmed the successful overexpression of ARID1A in the cholangiocarcinoma model. The difference in ARID1A expression intensity between the overexpression group and the control group was 5.334 times, P<0.0001. In addition, the E score of ARIDIA in the tumor tissues of all control group mice was less than or equal to the median of the H-score of the two groups of mice (H-score<4), and the daily score of ARIDIA in the tumor tissues of all overexpression group mice was greater than the median of the H-score of the two groups of mice (H-score>4). Representative immunohistochemical staining images of ARID1A in the control group and overexpression group and statistical graphs of relative expression intensity are shown in Figure 2. Figure 5 As shown in C.

[0084] Example 1: Method for constructing an efficacy prediction model for immunotherapy of biliary tract cancer based on ARID1A

[0085] Cholangiocarcinoma cells were taken from patients with cholangiocarcinoma, and the expression of ARID1A in the cholangiocarcinoma cells was analyzed. The following results were obtained:

[0086] Result (1): ARID1A expression in cholangiocarcinoma cells is high; or,

[0087] Results (2): ARID1A expression was low in cholangiocarcinoma cells.

[0088] The expression intensity of ARID1A in tumor tissues was evaluated using the H-score system. The formula of the H-score system is as follows: Hscore = (∑IS×AP), where IS represents the staining intensity and AP represents the percentage of positively stained cells. IS depends on the staining of the cells: no staining is 0 points; weak staining is 1 point; moderate staining is 2 points; strong staining is 3 points, and the percentage of AP-stained cells is: 0% is 0 points; 1%-25% is 1 point; 26%-50% is 2 points; 51%-75% is 3 points; 6%-100% is 4 points. The median of the H-score was set as the cutoff value, and the expression of ARIDIA in tumor tissues was divided into a high expression group (H-score>4) and a low expression group (H-score≤4).

[0089] Example 2: Composite agent under high expression of ARID1A and its use

[0090] Compound drug: anti-mouse PD-1 antibody and gemcitabine. Anti-mouse PD-1 antibody and gemcitabine are mixed at a mass ratio of 1:5.

[0091] The mouse intrahepatic cholangiocarcinoma model was established by hydrodynamic transfection of AKT / YAP(S127A) plasmids, and ARID1A overexpression plasmids were constructed and co-injected into mice by hydrodynamics to construct intrahepatic cholangiocarcinoma mice with ARID1A overexpression. After culturing mice with in situ cholangiocarcinoma and ARID1A overexpression for 14 days, the compound agent was diluted in 0.9% NaCl, injected intraperitoneally, and cultured for 24 days. The dosage of the compound agent for mice was measured by anti-mouse PD-1 antibody, and the dosage of anti-mouse PD-1 antibody was 5 mg / kg.

[0092] Example 3: Composite agent under high expression of ARID1A and its use

[0093] Preparation of hydroxylamine ester compounds: Add methionine to dichloromethane, stir at 0°C for 20 minutes, then add N,N-carbonyldiimidazole, stir and mix for 30 minutes, then heat to 30°C, then add acetohydroxamic acid to react for 4 hours. After the reaction is completed, concentrate under reduced pressure, and separate by column chromatography to obtain hydroxylamine ester compounds. The amount of methionine used is 6wt% of dichloromethane, the amount of N,N-carbonyldiimidazole used is 100wt% of methionine, and the amount of acetohydroxamic acid used is 100wt% of methionine. In column chromatography separation, the eluent is a mixture of methanol and water, and the eluent is a mixture of methanol and water in a volume ratio of 1:1.

[0094] Compound agent: anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine. Anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine are mixed in a mass ratio of 1:1:5.

[0095] The mouse intrahepatic cholangiocarcinoma model was established by hydrodynamic transfection of AKT / YAP(S127A) plasmids, and ARID1A overexpression plasmids were constructed and co-injected into mice by hydrodynamics to construct intrahepatic cholangiocarcinoma mice with ARID1A overexpression. After culturing mice with in situ cholangiocarcinoma and ARID1A overexpression for 14 days, the compound agent was diluted in 0.9% NaCl, injected intraperitoneally, and cultured for 24 days. The dosage of the compound agent for mice was measured by anti-mouse PD-1 antibody, and the dosage of anti-mouse PD-1 antibody was 5 mg / kg.

[0096] Example 4: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0097] A mouse intrahepatic cholangiocarcinoma model was established by hydrodynamic transfection of AKT / YAP (S127A) plasmids, without overexpressing ARID1A, that is, only mice with intrahepatic cholangiocarcinoma were obtained, and their intrahepatic cholangiocarcinoma cells were obtained.

[0098] Intrahepatic cholangiocarcinoma cells were inoculated on 6-well plates and cultured in culture medium at 37°C and 5% CO2. The culture medium consisted of culture medium and supplements, the culture medium was RPMI 1640, and the supplements were fetal bovine serum, penicillin / streptomycin, anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine. The amount of fetal bovine serum added to the culture medium was 10wt%, the amount of penicillin / streptomycin added was 1wt%, the amount of anti-mouse PD-1 antibody added was 5mg / L, the amount of hydroxylamine ester compound added was 2mg / L, and the amount of gemcitabine added was 25mg / L.

[0099] Example 5: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0100] The difference between this embodiment and embodiment 4 lies in the culture solution.

[0101] The culture medium is composed of a culture medium and a supplement, the culture medium is RPMI 1640, and the supplements are fetal bovine serum, penicillin / streptomycin, anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine. The amount of fetal bovine serum added to the culture medium is 10wt%, the amount of penicillin / streptomycin added is 1wt%, the amount of anti-mouse PD-1 antibody added is 5mg / L, the amount of hydroxylamine ester compound added is 5mg / L, and the amount of gemcitabine added is 25mg / L.

[0102] Example 6: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0103] The difference between this embodiment and embodiment 4 lies in the culture solution.

[0104] The culture medium is composed of a culture medium and a supplement, the culture medium is RPMI 1640, and the supplements are fetal bovine serum, penicillin / streptomycin, anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine. The amount of fetal bovine serum added to the culture medium is 10wt%, the amount of penicillin / streptomycin added is 1wt%, the amount of anti-mouse PD-1 antibody added is 10mg / L, the amount of hydroxylamine ester compound added is 2mg / L, and the amount of gemcitabine added is 30mg / L.

[0105] Example 7: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0106] The difference between this embodiment and embodiment 5 lies in the culture solution.

[0107] The culture medium is composed of a culture medium and a supplement, the culture medium is RPMI 1640, and the supplements are fetal bovine serum, penicillin / streptomycin, anti-mouse PD-1 antibody, hydroxylamine ester compound, glycyl D-glutamine and gemcitabine. The amount of fetal bovine serum added to the culture medium is 10wt%, the amount of penicillin / streptomycin added is 1wt%, the amount of anti-mouse PD-1 antibody added is 5mg / L, the amount of hydroxylamine ester compound added is 5mg / L, the amount of gemcitabine added is 25mg / L, and the amount of glycyl D-glutamine added is 1mg / L.

[0108] Example 8: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0109] The difference between this embodiment and embodiment 6 lies in the culture solution.

[0110] The culture medium is composed of a culture medium and a supplement, the culture medium is RPMI 1640, and the supplements are fetal bovine serum, penicillin / streptomycin, anti-mouse PD-1 antibody, hydroxylamine ester compound, glycyl D-glutamine and gemcitabine. The amount of fetal bovine serum added to the culture medium is 10wt%, the amount of penicillin / streptomycin added is 1wt%, the amount of anti-mouse PD-1 antibody added is 5mg / L, the amount of hydroxylamine ester compound added is 5mg / L, the amount of gemcitabine added is 25mg / L, and the amount of glycyl D-glutamine added is 2mg / L.

[0111] Comparative Example 1: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0112] The difference between this comparative example and Example 4 lies in the culture solution.

[0113] The culture medium is composed of a culture medium and a supplement, the culture medium is RPMI 1640, and the supplement is fetal bovine serum, penicillin / streptomycin and a hydroxylamine ester compound. The amount of fetal bovine serum added to the culture medium is 10wt%, the amount of penicillin / streptomycin added is 1wt%, and the amount of hydroxylamine ester compound added is 2mg / L.

[0114] Comparative Example 2: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0115] The difference between this comparative example and Example 4 lies in the culture solution.

[0116] The culture medium is composed of a culture medium and a supplement, the culture medium is RPMI 1640, and the supplements are fetal bovine serum, penicillin / streptomycin, anti-mouse PD-1 antibody and gemcitabine. The amount of fetal bovine serum added to the culture medium is 10wt%, the amount of penicillin / streptomycin added is 1wt%, the amount of anti-mouse PD-1 antibody added is 5mg / L, and the amount of gemcitabine added is 25mg / L.

[0117] Comparative Example 3: A method for inhibiting intrahepatic cholangiocarcinoma cells in mice

[0118] The difference between this comparative example and Example 4 lies in the culture solution.

[0119] The culture medium is composed of a culture medium and a supplement, the culture medium is RPMI 1640, and the supplements are fetal bovine serum, penicillin / streptomycin, anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine. The amount of fetal bovine serum added to the culture medium is 10wt%, the amount of penicillin / streptomycin added is 1wt%, the amount of penicillin / streptomycin added is 1wt%, the amount of anti-mouse PD-1 antibody added is 0.05mg / L, the amount of hydroxylamine ester compound added is 2mg / L, and the amount of gemcitabine added is 0.05mg / L.

[0120] Test example:

[0121] 1. Cytotoxicity

[0122] Intrahepatic bile duct cells of normal mice were cultured in RPMI1640 containing 10wt% fetal bovine serum and 1wt% penicillin / streptomycin at 37°C and 5% CO2. Cytotoxicity experiments were performed when the cell density reached 70-80%. The toxicity of hydroxylamine ester compounds to intrahepatic bile duct cells was tested by MTT method. The relationship between the amount of hydroxylamine ester compound added and RPMI 1640 was 100mg / L. A blank group and a control group were set up. No hydroxylamine ester compound was added to the blank group and the control group, no MTT solution was added to the blank group, and MTT solution was added to the control group.

[0123] Cell survival rate = (A 实验 -A空白 ) / (A 对照 -A 空白 ).

[0124] In the present invention, the hydroxylamine ester compound with the above concentration was used to conduct multiple experiments, and the average cell survival rate obtained was 99.92%, indicating that the hydroxylamine ester compound prepared in the present invention has basically no cytotoxicity.

[0125] 2. Cell inhibition rate

[0126] When the mouse intrahepatic cholangiocarcinoma cells are cultured according to Examples 4-8 and Comparative Examples 1-3, a blank control group is set up at the same time, that is, only RPMI 1640 containing 10wt% fetal bovine serum and 1wt% penicillin / streptomycin is used to culture the mouse intrahepatic cholangiocarcinoma cells for 30 days. The cell inhibition rate of the mouse intrahepatic cholangiocarcinoma cells cultured in Examples 4-8 and Comparative Examples 1-3 is calculated based on the mouse intrahepatic cholangiocarcinoma cells in the blank control group as a benchmark.

[0127] The present invention tested the cell inhibition rate of mouse intrahepatic cholangiocarcinoma cell growth obtained by the methods of Examples 4-8 and Comparative Examples 1-3. The test results are as follows: Figure 6 As shown, Examples 4-6 all have inhibitory effects on the growth of intrahepatic cholangiocarcinoma cells in mice. Comparison between Examples 4-6 shows that at the same dosage of the hydroxylamine ester compound, the higher the dosage of the anti-mouse PD-1 antibody and gemcitabine, the better the effect of the hydroxylamine ester compound. When the dosage of the anti-mouse PD-1 antibody and gemcitabine is constant, the higher the dosage of the hydroxylamine ester compound, the better the effect. Compared with Comparative Examples 1-3, Example 4 shows that the combined use of the anti-mouse PD-1 antibody, the hydroxylamine ester compound and gemcitabine is better than the single use of the hydroxylamine ester compound, and is also better than the combined use of the anti-mouse PD-1 antibody and gemcitabine. The anti-mouse PD-1 antibody and gemcitabine are used together, and the effect of the hydroxylamine ester compound requires a certain concentration of anti-mouse PD-1 antibody and gemcitabine. Then the anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine are used together to have an excellent effect of inhibiting the growth of mouse intrahepatic cholangiocarcinoma cells. When achieving the above-mentioned effect of the present invention, ARID1A overexpression is not required. In the aforementioned study of the present invention, it was found that when ARID1A is overexpressed, the anti-mouse PD-1 antibody and gemcitabine are used together to have a better effect. However, when the hydroxylamine ester compound of the present invention is used, ARID1A overexpression is not required to enhance the inhibition of mouse intrahepatic cholangiocarcinoma cell growth. Further, in the presence of anti-mouse PD-1 antibody, hydroxylamine ester compound and gemcitabine, glycyl D glutamine can also be added for use, and the use of glycyl D glutamine further enhances the inhibitory effect on the growth of mouse intrahepatic cholangiocarcinoma cells.

[0128] The embodiments and / or implementation methods described above are only used to illustrate the preferred embodiments and / or implementation methods for realizing the technology of the present invention, and are not intended to limit the implementation methods of the technology of the present invention in any form. Any technical personnel in this field may make slight changes or modifications to other equivalent embodiments without departing from the scope of the technical means disclosed in the content of the present invention, but they should still be regarded as technologies or embodiments that are essentially the same as the present invention.

[0129] This article uses specific examples to illustrate the principles and implementation methods of this application. The description of the above embodiments is only used to help understand the method and its core ideas of this application. The above is only the preferred implementation method of this application. It should be pointed out that due to the limitations of textual expression and the objective existence of infinite specific structures, ordinary technicians in this technical field can make several improvements, modifications or changes without departing from the principles of this application, and can also combine the above technical features in an appropriate manner; these improvements, modifications, changes or combinations, or the direct application of the concept and technical solution of the invention to other occasions without improvement, should be regarded as the scope of protection of this application.

Claims

1. A method for constructing an efficacy prediction model for immunotherapy of biliary tract cancer based on ARID1A, including: The expression of ARID1A in cholangiocarcinoma cells is analyzed and compared with the expression of ARID1A in normal cholangiocarcinoma cells, and any of the results (1)-(2) is obtained: Results (1): ARID1A expression in cholangiocarcinoma cells was high, indicating a good prognosis; Results (2): ARID1A expression in cholangiocarcinoma cells was low, indicating a poor prognosis; The products used for treatment corresponding to the results (1)-(2) include at least anti-PD-1 antibodies and gemcitabine, and the products used also include hydroxylamine ester compounds; In the preparation of the hydroxylamine ester compound, methionine is added to dichloromethane, stirred at 0-10°C for 10-30 minutes, then N,N-carbonyldiimidazole is added, stirred and mixed for 10-60 minutes, and then the temperature is raised to 2-40°C, and then acetohydroxamic acid is added to react for 2-6 hours. After the reaction is completed, it is concentrated under reduced pressure and separated by column chromatography to obtain the hydroxylamine ester compound.

2. The method for constructing an efficacy prediction model for immunotherapy of biliary tract cancer based on ARID1A according to claim 1, characterized in that: The dosage of the anti-PD-1 antibody is 1-10 mg / kg, and the dosage of gemcitabine is 5-50 mg / kg.

3. The method for constructing an efficacy prediction model for immunotherapy of biliary tract cancer based on ARID1A according to claim 1, characterized in that: The usage amount of the hydroxylamine ester compound is 1-10 mg / kg.

4. Use of anti-PD-1 antibodies, gemcitabine and hydroxylamine ester compounds in the preparation of drugs for the treatment of biliary tract cancer. In the preparation of the hydroxylamine ester compound, methionine is added to dichloromethane, stirred at 0-10°C for 10-30 minutes, and then N,N-carbonyldiimidazole is added. After stirring and mixing for 10-60 minutes, the temperature is raised to 2-40°C, and then acetohydroxamic acid is added to react for 2-6 hours. After the reaction is completed, it is concentrated under reduced pressure and separated by column chromatography to obtain the hydroxylamine ester compound.

5. The use according to claim 4, characterized in that: The ratio of anti-PD-1 antibody, hydroxylamine ester compound and gemcitabine is 1:0.1-10:0.5-50.